Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AGM Statement

21st May 2009 12:15

RNS Number : 6555S
TyraTech, Inc.
21 May 2009
 



For immediate release

21 May 2009

TYRATECH, INC.

("TyraTech" or "the Company")

ANNUAL GENERAL MEETING STATEMENT

London, UK, 21 May 2009 - TyraTech, Inc. (AIM: TYR), a leading independent novel clean technology company for human, animal and environmental health, announces that at its 2009 Annual General Meeting which was held at 12 noon today, all resolutions put to shareholders were duly passed.

At today's Annual General Meeting, Douglas Armstrong Ph.D., Chief Executive Officer of TyraTech, made the following comment:

"TyraTech has continued to make significant progress with its overall business and we have been very pleased to sign new key distribution partnerships with market leaders in our various product areas.

"We look forward to informing the market as further progress is made."

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7723

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker/Clare Terlouw +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

MaryߛJane Elliott / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

www.buchanan.uk.com

About TyraTech

 

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech, which already has a product on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech's technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors. TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visit www.tyratech.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMMGGZKMMGGLZM

Related Shares:

Tyratech
FTSE 100 Latest
Value8,809.74
Change53.53